Research area · week to 3 Oct 2026

Nanoplatforms for cancer theranostics

Moving in bioRxiv, Nature Communications, Applied and environmental microbiology, Biotechnology advances, Cell Reports, Frontiers in Genetics, Gut, Nature Cancer.

Moved this week: 0

Rebuilt 3 October 2026 at 3:19 pm AEST

Moved this week

Everything that moved →

Nothing in this area has moved yet this week.

Latest in Nanoplatforms for cancer theranostics

Newest first · last 60 days

Increased extracellular fluid viscosity drives M2-like macrophage polarization to promote breast cancer progression and immunotherapy resistance.
Cell Reports · 24 Sept 2026 · Journal Article
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42789388
Open in JClub
Research progress on nanomaterials in promoting phage function and application.
Applied and environmental microbiology · 23 Sept 2026 · Review
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42573265
Open in JClub
Modular engineered colorectal tumor microenvironments for immuno-oncology research and drug development
bioRxiv · 23 Sept 2026 · Preprint
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.06.02.729459
Open in JClub
Harnessing endogenous carbon monoxide for cancer-selective drug synthesis.
Nature Communications · 17 Sept 2026 · Journal Article
Endogenous carbon monoxide enables cancer-specific drug synthesis using a biocompatible palladium platform, producing cytotoxic agents that suppress tumor growth.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42754578
Open in JClub
Beyond local control: radiotherapy-immunotherapy combinations from in situ vaccination to systemic immune remodeling.
Frontiers in Genetics · 17 Sept 2026 · Review
Combining radiotherapy with immunotherapy can enhance systemic antitumor immunity, but success depends on balancing local control with immune activation, with some approaches showing promise in specific cancers.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42820221
Open in JClub
Quantum Sensing Reveals Chemotherapy Induced Persistent Oxidative Footprints in Fixed Brain Cancer Cells
bioRxiv · 7 Sept 2026 · Preprint
Read the brief in JClub
- Open access
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.1101/2025.07.27.666994
Open in JClub
Imaging the hallmarks of cancer.
Nature Reviews Cancer · 1 Sept 2026 · Review
Non-invasive imaging of cancer hallmarks enables real-time monitoring and stratification of tumors, with some techniques already impacting clinical treatment decisions.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42373751
Open in JClub
Targeting claudins in cancer.
Nature Reviews Drug Discovery · 1 Sept 2026 · Review
Targeting claudins offers a promising new approach, with zolbetuximab becoming the first FDA-approved CLDN-18.2-targeted antibody for gastric cancer treatment.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42209790
Open in JClub
Bacterial engineering for cancer therapy.
Nature Cancer · 1 Sept 2026 · Review
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42243277
Open in JClub
Ex vivo live macrophage engineering strategies in immunotherapy.
Biotechnology advances · 24 Aug 2026 · Review
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42637181
Open in JClub
A cuproptosis-inducing covalent organic framework synergizes with oncolytic virus for tumor radiotherapy.
Nature Communications · 21 Aug 2026 · Journal Article
A copper-based covalent organic framework combined with oncolytic virus enhances radiotherapy efficacy by inducing cuproptosis in radioresistant tumors, achieving durable immune responses.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42764348
Open in JClub
Circulating extracellular vesicles carrying PD-1, PD-L1 and CTLA-4 inform resistance to anti-PD-L1-based therapy in HCC.
Gut · 6 Aug 2026 · Journal Article
Read the brief in JClub
- Open access
- 3 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42562419
Open in JClub
Lung-Selective Immune Reprogramming via In Situ Red Blood Cell Hitchhiking Nanoparticles
bioRxiv · 6 Aug 2026 · Preprint
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.02.27.708550
Open in JClub
A covalent PFKL activator suppresses tumor growth.
Nature Chemical Biology · 5 Aug 2026 · Journal Article
A covalent PFKL activator enhances glycolysis and delivers a CPT2 inhibitor, effectively suppressing tumor growth in vitro and in vivo.
- Open access
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42557312
Open in JClub

Follow this area in the app

Journals this month

All journals →

Moving areas, week to 3 Oct 2026

All research areas →

Read

Moved this week

Latest in Nanoplatforms for cancer theranostics

Browse JClub